Xap Therapeutics use of commercial, fully anonymised CD34+ cells

• Research type

  Research Study

• Full title

  This project aims to study the differentiation of CD34+ cells into megakaryocytes and fragmentation into platelets (1-4 weeks culture time). Cultured megakaryocytes and platelets derived from fully anonymised screened cord or peripheral blood will be used for further analysis in order to help characterise megakaryocytes and platelets derived from by other means.

• IRAS ID

  305200

• Contact name

  Laurent S Jespers

• Contact email

  celeste.pallant@xaptherapeutics.com

• Sponsor organisation

  Xap Therapeutics LTD

• Duration of Study in the UK

  3 years, 0 months, 0 days

• Research summary

  This project aims to study the differentiation of CD34+ cells into megakaryocytes and fragmentation into platelets (1-4 weeks culture time). Cultured megakaryocytes and platelets derived from fully anonymised screened cord or peripheral blood will be used for further analysis in order to help characterise megakaryocytes and platelets derived by other means.

• REC name

  London - Brighton & Sussex Research Ethics Committee

• REC reference

  22/PR/0326

• Date of REC Opinion

  5 Apr 2022

• REC opinion

  Further Information Favourable Opinion